Showing results (1-10 of 89) with videos related to
Sort By:
Pageof 9
Expert Review of Hematology|July 24, 2020
An evaluation of polatuzumab vedotin for the treatment of patients with diffuse large B-cell lymphomaMoneeza Walji, Sarit AssoulineExpert Review of Hematology|January 12, 2021
A review of FDA-approved acute myeloid leukemia therapies beyond '7 + 3'Alexandre Bazinet, Sarit AssoulineFuture Oncology (London, England)|October 26, 2023
Mosunetuzumab and the emerging role of T-cell-engaging therapy in follicular lymphomaSarah Matarasso, Sarit AssoulineExpert Review of Hematology|October 11, 2023
Immunotherapy for myelodysplastic syndrome and acute myeloid leukemia: where do we stand?David R Spillane, Sarit AssoulineCanadian Liver Journal|August 22, 2022
Rituximab-induced autoimmune hepatitis: A case study and literature reviewPolymnia Galiatsatos, Sarit Assouline, Adrian Gologan, et al.Blood Advances|April 27, 2021
Treating lymphoma is now a bit EZ-erRyan D Morin, Sarah E Arthur, Sarit AssoulineCancers|November 12, 2013
The Development of Novel Therapies for the Treatment of Acute Myeloid Leukemia (AML)Sarit Assouline, Eftihia Cocolakis, Katherine L B BordenCurrent Treatment Options in Oncology|May 2, 2020
PI3K Inhibitors and Their Role as Novel Agents for Targeted Therapy in LymphomaVladimir Sapon-Cousineau, Sasha Sapon-Cousineau, Sarit AssoulineCritical Reviews in Oncology/Hematology|May 19, 2022
Validity of event-free survival as a surrogate endpoint in haematological malignancy: Review of the literature and health technology assessmentsSarit Assouline, Adriana Wiesinger, Clare Spooner, et al.Transfusion|January 31, 2006
Comparison of peripheral blood progenitor cell yield from standard chemotherapy used in the treatment of lymphoid malignancies and high-dose cyclophosphamide: a retrospective review of 141 patientsSarit Assouline, Marie-Pierre Sylvestre, Philippe Carriere, et al.Pageof 9